HC Wainwright Has Negative View of Kairos Pharma Q3 Earnings

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) – Stock analysts at HC Wainwright reduced their Q3 2025 earnings per share estimates for shares of Kairos Pharma in a research note issued on Wednesday, August 13th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of ($0.10) per share for the quarter, down from their previous estimate of ($0.07). HC Wainwright also issued estimates for Kairos Pharma’s Q4 2025 earnings at ($0.12) EPS, FY2026 earnings at ($0.33) EPS, FY2027 earnings at ($0.53) EPS and FY2028 earnings at ($0.61) EPS.

Separately, D. Boral Capital reaffirmed a “buy” rating and set a $9.00 target price on shares of Kairos Pharma in a research note on Wednesday, July 16th.

Kairos Pharma Trading Down 3.2%

NYSEAMERICAN KAPA opened at $1.20 on Friday. The stock’s 50-day moving average price is $0.81 and its two-hundred day moving average price is $0.97. The company has a market cap of $24.89 million and a PE ratio of -3.53. Kairos Pharma has a 1 year low of $0.40 and a 1 year high of $4.00.

Institutional Investors Weigh In On Kairos Pharma

A hedge fund recently bought a new stake in Kairos Pharma stock. XTX Topco Ltd acquired a new stake in Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 62,746 shares of the company’s stock, valued at approximately $44,000. XTX Topco Ltd owned 0.31% of Kairos Pharma at the end of the most recent quarter.

About Kairos Pharma

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.